GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity
- 27 August 1996
- journal article
- Published by Elsevier in Regulatory Peptides
- Vol. 65 (1) , 45-53
- https://doi.org/10.1016/0167-0115(96)00071-7
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The pharmacology of GR203040, a novel, potent and selective non‐peptide tachykinin NK1 receptor antagonistBritish Journal of Pharmacology, 1995
- The broad‐spectrum anti‐emetic activity of the novel non‐peptide tachykinin NK1 receptor antagonist GR203040British Journal of Pharmacology, 1995
- Discovery of an Orally Bioavailable NK1 Receptor Antagonist, (2S,3S)-(2-Methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with Potent Antiemetic ActivityJournal of Medicinal Chemistry, 1995
- The anti‐emetic effects of CP‐99,994 in the ferret and the dog: role of the NK1 receptorBritish Journal of Pharmacology, 1995
- Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferretsEuropean Journal of Pharmacology, 1993
- The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferretEuropean Journal of Pharmacology, 1993
- Morphine 6‐glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferretBritish Journal of Pharmacology, 1992
- Review paperAnti-Cancer Drugs, 1992
- Selective blockade of cytotoxic drug-induced emesis by 5-HT3 receptor antagonists in Suncus murinus.The Japanese Journal of Pharmacology, 1991
- The effect on motion sickness and oculomotor function of GR 38032F, a 5- HT3-receptor antagonist with anti-emetic properties.British Journal of Clinical Pharmacology, 1989